Sunday, November 15, 2026

Peer-Reviewed Clinical Evidence Platform

The research that matters, without the jargon.

Peer-reviewed breakthroughs in plain English alongside verified outcomes, evidence grades, and clinical study details for everyone from everyday readers to medical students.

ClearMed Editorial Digest500 briefings across 12 specialties121 Phase III & clinical practice

Indexed from PubMed, NEJM, The Lancet, JAMA, Nature MedicineSaved Library

Health Hubs:

Stage: Evidence:

Showing 35 briefings

Reset all filters

Gastroenterology

Gastroenterology Clinical Briefings

Peer-Reviewed Clinical Digests · Verified Scientific Media

Gastroenterology editorial photograph for Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial

GASTROENTEROLOGY · PHASE III

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial

Aspirin After Colon Cancer: A Surprising Setback for a Common Drug. Taking aspirin after surgery for colon cancer that spread to the liver did not prevent the cancer from returning and was linked to worse survival and more serious side effects.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyNov 15, 2026

GASTROENTEROLOGY · CLINICAL PRACTICE

New Fiber Supplement Shows Promise for Irritable Bowel Syndrome

A novel fiber supplement may effectively manage IBS symptoms and gut-related anxiety without causing common digestive distress. This discovery offers a promising new non-pharmacological option for millions suffering from Irritable Bowel Syndrome, potentially alleviating symptoms without common digestive side effects.

2/5 Preclinical

Evidence Meter · 2/5

Animal & Preclinical Data

Demonstrated in living animal models before large-scale human safety and dosing trials begin.

1 min readScienceDailyNov 15, 2026

GASTROENTEROLOGY · REAL-WORLD COHORT

Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study

Silent Liver Damage: A Hidden Epidemic in China's Adult Population. Liver scarring and fatty liver disease are widespread among Chinese adults, largely fueled by metabolic issues and alcohol.

4/5 Strong Trial

Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readThe Lancet Gastroenterology & HepatologyNov 15, 2026

GASTROENTEROLOGY · REAL-WORLD COHORT

Genetic variants and the risk of renal impairment in decompensated cirrhosis: a multi-ancestry genome-wide association study

Unlocking the Genetic Link Between Liver Failure and Kidney Damage. Scientists have pinpointed a specific gene, SUSD1, that significantly increases the risk of kidney problems in people with severe liver disease.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyNov 15, 2026

GASTROENTEROLOGY · CLINICAL PRACTICE

AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis

The guideline emphasizes early diagnosis, optimization of first-line therapy, risk-based treatment escalation, symptom management, and prevention of post-transplantation disease recurrence to improve patient outcomes and quality of life. Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with progressive fibrosis (tissue scarring), cirrhosis, liver transplantation, and premature risk of death.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readGastroenterologyNov 15, 2026

GASTROENTEROLOGY · PHASE III

Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial

Izalontamab brengitecan significantly improved PFS and OS vs chemotherapy in patients with recurrent or metastatic ESCC whose disease had progressed after first-line treatment. These findings support izalontamab brengitecan as a new second-line treatment for this population in China.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readJAMANov 12, 2026

GASTROENTEROLOGY · PHASE III

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study

In patients with MASH, 48 weeks of pemvidutide treatment led to significant reductions in non-invasive tests of MASH inflammation and fibrosis (tissue scarring), suggesting continued improvement in liver health. These data warrant the continued investigation of pemvidutide in a Phase 3 trial.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyNov 11, 2026

GASTROENTEROLOGY · RANDOMIZED CLINICAL TRIAL

Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial

Early top-down anti-TNF treatment from diagnosis was associated with improved long-term outcomes at 5 years compared with step-up treatment and is suggestive of a disease-modifying effect in Crohn's disease. The PROFILE trial previously reported better 48-week outcomes for patients with Crohn's disease who received top-down anti-TNF treatment from diagnosis, compared with a conventional step-up strategy.

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & HepatologyNov 11, 2026

GASTROENTEROLOGY · REAL-WORLD COHORT

Remote patient management reduces liver-related hospitalizations in patients with acutely decompensated cirrhosis

CiRPM enrollment was associated with fewer liver-related hospitalizations, particularly among patients with ALD and CLIF-C AD ≥60, supporting targeted remote management as a scalable post-discharge strategy for this high-risk population. Patients with decompensated cirrhosis experience frequent hospitalizations, yet evidence supporting remote post-discharge care remains limited.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readHepatology (baltimore, Md.)Nov 9, 2026

GASTROENTEROLOGY · GUIDELINE / OPINION

AASLD EXPO: Diagnosis and management of hepatitis delta virus (HDV) infection

All HBsAg positive individuals should be screened for HDV. All adults with chronic HDV and compensated liver disease are candidates for HDV therapy.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readHepatology (baltimore, Md.)Nov 6, 2026

GASTROENTEROLOGY · PHASE III

Treatment with elafibranor to normalize alkaline phosphatase in patients with primary biliary cholangitis and incomplete response to ursodeoxycholic acid: Results from the phase III randomized controlled ELSPIRE trial

These results support elafibranor as second-line treatment with UDCA for patients with PBC and ALP >1-<1.67× ULN, with ALP normalization as an achievable treatment goal. Definitions of primary biliary cholangitis (PBC) treatment response commonly include alkaline phosphatase (ALP) <1.67× upper limit of normal (ULN).

5/5 Gold Standard

Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readHepatology (baltimore, Md.)Nov 5, 2026

GASTROENTEROLOGY · REAL-WORLD COHORT

ATTEST 2027: A Framework for AI Transparency Tiered by Evidentiary Stakes

The goal is to make AI's role in evidence generation transparent to readers, reviewers, and editors so they can evaluate the integrity of scientific findings. The framework is operationalized by a declaration checklist that authors complete at submission.

3/5 Observational

Evidence Meter · 3/5

Real-World Observation

Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.

1 min readHepatology (baltimore, Md.)Nov 5, 2026

Showing 12 of 35 medical briefings

Interactive Fact Check